Mei Pharma, INC 10-Q quarterly reports

Lite Strategy Inc. reports significant shift towards digital asset treasury strategy, with substantial digital asset holdings and related income/losses impacting financial results.

Lite Strategy, Inc. shifts focus from pharmaceuticals to a Litecoin treasury strategy, reporting a significant net loss in its latest quarterly filing.

Lite Strategy, Inc. shifted its primary strategy to include Litecoin as a reserve asset, reporting a significantly reduced net loss for the quarter ended September 30, 2025.

MEI Pharma announces Q3 2025 results, highlighting a strategic shift towards evaluating strategic alternatives, including a potential wind-down, and the sale of ME-344.

MEI Pharma announces Q2 2025 financial results amid strategic shift, including the sale of ME-344 and discontinuation of voruciclib clinical development.

MEI Pharma reports its Q1 2025 financial results, highlighting a significant revenue decrease due to the termination of a key collaboration agreement, alongside strategic shifts including a reduction in force and the sale of a key asset.

MEI Pharma's Q3 2024 report highlights a strategic shift towards prioritizing voruciclib development and a decision against a second capital return, alongside a significant revenue increase due to the termination of a collaboration agreement.

MEI Pharma has updated its employment agreement with its Chief Medical Officer and released its financial results for the quarter ended December 31, 2023, showing a significant revenue increase due to a collaboration agreement termination.